TGFB1 and cancer: Active initiatives to further the understanding of the role that aberrant TGFβ/SMAD3 signaling plays in the sensitivity to CDK inhibitor therapy will lead to more precise implementation of this cancer treatment modality for the management of breast and other cancers in the near future.